Proactive
Proactive is the leading digital news and media group, dominating the "Small-Mid Cap" companies investor sector across four continents. Proactive Investors Australia is a part of the largest global financial investor network with offices in Australia, Europe, Asia and North America.
See more information about Proactive
Humanigen showing positive results for cancer drug lenzilumab, also used to treat patients hospitalized with coronavirus
Humanigen Inc (NASDAQ:HGEN) is in the early stages of work on a drug designed to reduce the sometimes dangerous side effects associated with a cancer therapy involving altered T-cells.
A goal is to improve the safety of so-called CAR-T therapies, used in the treatment of children with acute lymphoblastic leukemia and adults with advanced lymphomas. A frequent side-effect is cytokine release syndrome, which can include fever, nausea, headache, rash, rapid heartbeat, low blood pressure and trouble breathing. Reactions are often mild but occasionally life-threatening.
The key drug candidate for the Burlingame, California, company is lenzilumab, a recombinant monoclonal antibody that neutralizes a substance that promotes growth of white blood cells but is also tied to inflammations that can occur during CAR-T therapies and lead to side effects. Pre-clinical work involving mice shows lenzilumab is effective in preventing the side effects and may make the CAR-T therapies more effective, according to Humanigen.
The company has completed a Phase 1 clinical trial of patients with a type of leukemia conducted to identify the recommended Phase 2 dose of lenzilumab and to assess its safety. The company is planning on starting pivotal studies this year involving CAR-T and hopes to complete them by the end of 2020.
It has also initiated a Phase 3 clinical trial to evaluate lenzilumab combined with remdesivir vs. remdesivir alone as a treatment for severe coronavirus (COVID-19) patients.
Humanigen is also looking at two other drug candidates: ifabotuzumab and HGEN005.
Other Proactive news
- AgraFlora Organics International receives cannabis edibles processing license for its Winnipeg manufacturing facility
2020-12-14 - Delta 9 Cannabis debuts new decontamination pods to help fight coronavirus
2020-12-08 - XPhyto touts rapid 25-minute RT-PCR lab test for coronavirus detection
2020-10-28 - One World Lithium to start proof of concept program testing potential lithium separation technology
2020-10-27 - Revive Therapeutics commits to 10 sites for Phase 3 coronavirus trial of bucillamine
2020-10-26
